Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:CABA 31 October 2025 - 22 January 2026

Cabaletta Bio stock jumps 11% premarket after insider buying cluster hits the tape

Cabaletta Bio stock jumps 11% premarket after insider buying cluster hits the tape

Cabaletta Bio shares rose about 11% premarket Thursday after insider-buying reports, trading at $2.60 versus Wednesday’s $2.34 close. CEO Steven Nichtberger bought 45,000 shares Jan. 21, with other executives and directors also purchasing stock, SEC filings show. Trading volume Wednesday hit 2.09 million shares. The company is developing an experimental CD19 CAR-T therapy for autoimmune diseases.
22 January 2026
·
Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Cabaletta Bio shares surged up to 46% on Oct. 31, closing at $3.61 after strong CAR-T therapy data, with trading volume hitting 35.7 million shares. Phase 1/2 results showed major improvements in myositis and systemic sclerosis, and durable lupus nephritis remissions. The company remains pre-revenue, holding $194.7 million cash as of June 30. Wall Street analysts mostly rate CABA a “Buy,” with targets averaging $13–15.
31 October 2025
··
Go toTop